Cambient Family Office’s Novartis NVS Stock Holding History

Cambient Family Office’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$668K	Hold	4,264	–	–	0.08%	138
2026 Q1	$651K	Hold	4,264	–	–	0.09%	129
2025 Q4	$588K	Buy	+4,264	New	+$558K	0.08%	123

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Cambient Family Office's NVS Position: Q2 2026 in Review

Cambient Family Office held its Novartis (NVS) position steady in Q2 2026 at 4,264 shares worth $668K. The position accounts for 0.08% of the portfolio, ranked #138.

Cambient Family Office first reported a position in NVS in Q4 2025 and has held it in 3 quarters since. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Cambient Family Office held 4,264 shares of Novartis worth $668K as of Q2 2026.
Cambient Family Office left its Novartis share count unchanged in Q2 2026.
Novartis made up 0.08% of Cambient Family Office's portfolio in Q2 2026, its #138 holding.
Cambient Family Office first reported a position in Novartis in Q4 2025 and has held it in 3 quarters since.
1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Cambient Family Office's 13F filing for Q2 2026, filed 13 Aug 2026.